Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Hungary, Romania, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||R1.06|
|52 Week High||R0.43|
|52 Week Low||R1.30|
|1 Month Change||89.29%|
|3 Month Change||76.67%|
|1 Year Change||76.67%|
|3 Year Change||-86.63%|
|5 Year Change||-96.10%|
|Change since IPO||-90.45%|
Recent News & Updates
|ASC||ZA Pharmaceuticals||ZA Market|
Return vs Industry: ASC underperformed the ZA Pharmaceuticals industry which returned 85.9% over the past year.
Return vs Market: ASC exceeded the ZA Market which returned 19% over the past year.
Stable Share Price: ASC is more volatile than 75% of ZA stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: ASC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of ZA stocks.
About the Company
|2008||n/a||Mark James Van Sardi||https://www.ascendishealth.com|
Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Hungary, Romania, and internationally. The company operates through Consumer Health, Pharma, and Medical segments. It offers body and skin products; and natural supplements, multi-vitamin and mineral supplements, micronutrient supplements, nutraceutical supplements, vitamins, minerals, and homeopathic and herbal products under the Bettaway, Chela-Fer, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Nimue, Scitec, Solal, and Vitaforce brand names.
Ascendis Health Fundamentals Summary
|ASC fundamental statistics|
Is ASC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ASC income statement (TTM)|
|Cost of Revenue||R1.30b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-3.42|
|Net Profit Margin||-74.11%|
How did ASC perform over the long term?See historical performance and comparison
Is Ascendis Health undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ASC (ZAR1.06) is trading below our estimate of fair value (ZAR43.55)
Significantly Below Fair Value: ASC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ASC is unprofitable, so we can't compare its PE Ratio to the African Pharmaceuticals industry average.
PE vs Market: ASC is unprofitable, so we can't compare its PE Ratio to the ZA market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ASC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ASC is good value based on its PB Ratio (1.5x) compared to the XF Pharmaceuticals industry average (2x).
How is Ascendis Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ascendis Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Ascendis Health performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ASC is currently unprofitable.
Growing Profit Margin: ASC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ASC is unprofitable, and losses have increased over the past 5 years at a rate of 55.5% per year.
Accelerating Growth: Unable to compare ASC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10%).
Return on Equity
High ROE: ASC has a negative Return on Equity (-314.56%), as it is currently unprofitable.
How is Ascendis Health's financial position?
Financial Position Analysis
Short Term Liabilities: ASC's short term assets (ZAR9.8B) do not cover its short term liabilities (ZAR9.9B).
Long Term Liabilities: ASC's short term assets (ZAR9.8B) exceed its long term liabilities (ZAR250.3M).
Debt to Equity History and Analysis
Debt Level: ASC's debt to equity ratio (1322.1%) is considered high.
Reducing Debt: ASC's debt to equity ratio has increased from 67.4% to 1322.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ASC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ASC is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 30.4% per year.
What is Ascendis Health current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ASC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ASC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ASC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ASC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ASC is not paying a notable dividend for the ZA market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ASC's dividend in 3 years as they are not forecast to pay a notable one for the ZA market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark James Van Sardi (52 yo)
Mr. Mark James Van Lill Sardi, CA (SA) is Chief Executive Officer and an Executive Director at Ascendis Health Limited since October 14, 2019. Mr. Sardi served as Joint Deputy Chief Executive of Cipla Medp...
CEO Compensation Analysis
Compensation vs Market: Mark James Van's total compensation ($USD759.01K) is above average for companies of similar size in the ZA market ($USD278.61K).
Compensation vs Earnings: Mark James Van's compensation has increased whilst the company is unprofitable.
Experienced Management: ASC's management team is considered experienced (2.4 years average tenure).
Experienced Board: ASC's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ascendis Health Limited's employee growth, exchange listings and data sources
- Name: Ascendis Health Limited
- Ticker: ASC
- Exchange: JSE
- Founded: 2008
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: R512.459m
- Shares outstanding: 483.45m
- Website: https://www.ascendishealth.com
- Ascendis Health Limited
- 31 Georgian Crescent East
- South Africa
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/25 21:42|
|End of Day Share Price||2021/10/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.